---

Transaction Summary

• Completed a $100M IPO in 2014
• Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• www.molecularpartners.com
• IPO

Related News

• Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®
• Allergan and Molecular Partners Enter into an Exclusive Alliance
• Molecular Partners and Astra Zeneca Announce Collaboration
• Molecular Partners Comments on Allergan’s Progress in Phase IIa Retinal Disease Trial using anti-VEGF DARPin